Dragon Pharma — SARMs
4 SARM products covering the full potency spectrum — from mild first-cycle Ostarine through the strongest available SARM LGD-4033, the full AR agonist S23, and YK-11 with its unique dual AR agonism and myostatin inhibition mechanism. All oral tablets, independently third-party tested.
SARMs
Showing 1–4 of 4 results
Dragon Pharma SARMs — 4 Products
Selective Androgen Receptor Modulators are non-steroidal (with one notable exception) synthetic ligands designed to activate androgen receptors with tissue selectivity — anabolic effects in muscle and bone with reduced androgenic activity in prostate and scalp compared to traditional AAS. Dragon Pharma's four SARM products cover the complete potency hierarchy from entry-level to most potent, with independent third-party testing confirming compound identity and dosage accuracy for all four.
Ostarine MK-2866 — The Entry SARM
Ostarine (MK-2866, Enobosarm) is the most clinically studied SARM — Phase III human trials in cancer cachexia at 3mg/day provide the most extensive human pharmacokinetic and safety data of any SARM in the range. Mild partial AR agonist producing 1-3kg lean mass gain in a typical 8-week cycle at 25mg/day with minimal HPG suppression (20-40% LH/FSH reduction). The appropriate starting point for users new to SARMs, and the compound of choice for injury recovery and lean mass preservation during cutting phases where full AAS suppression is undesirable.
LGD-4033 Ligandrol — The Strongest Available SARM
LGD-4033 (Ligandrol, VK5211) is the most anabolically potent widely available SARM — Phase I human trial (Basaria et al.) demonstrated dose-dependent lean mass gains at just 0.1-1.0mg/day, far below the 5-15mg/day performance doses. Full AR agonist producing 3-5kg lean mass in a typical 8-week cycle at 10mg/day. Significant HPG suppression at performance doses (50-70% testosterone reduction) requiring the same PCT attentiveness as an injectable AAS cycle — Clomid or Nolvadex for 4-6 weeks post-cycle.
S23 Mastorin — Full AR Agonist, Cutting Focus
S23 (Mastorin) was originally investigated as a male hormonal contraceptive — at sufficient doses it produces complete reversible spermatogenesis suppression, which reveals the critical practical reality: S23 is the most suppressive SARM in the range. Full AR agonist with the highest binding affinity of any available SARM, producing hardness, lean mass preservation and body fat reduction. Profile best suited to cutting and recomposition phases. HPG suppression depth requires the same PCT rigour as an injectable AAS cycle; HCG use during or before PCT is strongly advisable.
YK-11 — Dual AR Agonism and Myostatin Inhibition
YK-11 is the pharmacological outlier of the SARM category — structurally a synthetic steroid derived from DHT rather than a non-steroidal small molecule like the other three. It simultaneously acts as a partial AR agonist and upregulates Follistatin production in muscle cells, which inhibits myostatin (the endogenous ceiling on muscle growth). The dual mechanism — direct AR activation plus removal of the myostatin growth ceiling — is theoretically the most comprehensive anabolic signalling from a single oral compound. Evidence base is currently in vitro only (Kanno et al., 2013) with no published animal or human in vivo data — the most important caveat in the SARM range.
SARMs and PCT — What You Need to Know
All four SARMs in the Dragon Pharma range suppress the HPG axis to varying degrees and require appropriate post-cycle management. The "no PCT needed" claim commonly applied to SARMs is inaccurate for any cycle of meaningful dose and duration. Suppression hierarchy: S23 (highest, near-complete) > LGD-4033 (significant) > YK-11 (significant) > Ostarine (mild-moderate). PCT timing for all four: begin 24-48 hours after the last tablet — oral SARMs have relatively short half-lives (12-36 hours) and clear quickly. Standard PCT with Clomid or Nolvadex for 4-6 weeks is appropriate after LGD-4033, S23 and YK-11 cycles. Ostarine at 25mg/day for 8 weeks warrants at minimum a 4-week PCT.
Frequently Asked Questions
Traditional anabolic-androgenic steroids (AAS) are steroidal compounds that activate androgen receptors throughout the body — including prostate, scalp and other androgenic tissues — producing both anabolic and androgenic effects. SARMs (Selective Androgen Receptor Modulators) are primarily non-steroidal ligands designed to activate androgen receptors with tissue selectivity — greater anabolic effect in muscle and bone relative to androgenic effects in prostate and scalp. In practice the selectivity is partial rather than absolute. Note: YK-11 is the exception — it is structurally a synthetic steroid despite being categorised as a SARM due to its partial AR agonist and tissue-selective properties.
Ostarine (MK-2866) is the appropriate first SARM — it has the most extensive human clinical data (Phase III), the mildest suppression profile, and provides meaningful lean mass and strength benefit at 25mg/day over 6-8 weeks. This allows assessment of individual response to AR modulation before progressing to more potent and more suppressive compounds like LGD-4033. Starting with LGD-4033, S23 or YK-11 as a first SARM commits to heavier suppression without the baseline experience to assess response.
Yes — for any cycle of meaningful dose and duration. All four Dragon Pharma SARMs suppress LH and FSH to varying degrees. LGD-4033 at 10mg/day for 8 weeks produces 50-70% testosterone suppression requiring full SERM PCT. S23 can produce near-complete suppression requiring PCT as rigorous as after an injectable AAS cycle. Ostarine at 25mg/day for 8 weeks warrants at minimum a 4-week PCT. Begin PCT 24-48 hours after the last SARM tablet for all four compounds.
Yes — SARMs can be added to AAS cycles as oral compounds providing additional AR activation without aromatisation. LGD-4033 is most commonly stacked with a testosterone base as an oral mass-building addition. S23 is added to cutting cycles alongside non-aromatising injectables like Masteron or Primobolan for enhanced hardness. When stacking SARMs with AAS, PCT requirements are driven by the AAS ester timing — the SARM's shorter clearance means it does not extend PCT timing beyond the injectable's requirements.
Yes — all four SARMs are detectable in urine through WADA-accredited anti-doping panels. WADA includes SARMs on the prohibited list under the Anabolic Agents category. Detection windows extend several weeks beyond the last dose due to metabolite persistence in urine. Competitive athletes in tested sports should not use any SARM. Detection methodology for SARMs has improved significantly since 2015 — assuming SARMs are undetectable is incorrect.